Abstract
Tissues derive ATP from two pathways—glycolysis and the tricarboxylic acid (TCA) cycle coupled to the electron transport chain. Most energy in mammals is produced via TCA metabolism1. In tumours, however, the absolute rates of these pathways remain unclear. Here we optimize tracer infusion approaches to measure the rates of glycolysis and the TCA cycle in healthy mouse tissues, Kras-mutant solid tumours, metastases and leukaemia. Then, given the rates of these two pathways, we calculate total ATP synthesis rates. We find that TCA cycle flux is suppressed in all five primary solid tumour models examined and is increased in lung metastases of breast cancer relative to primary orthotopic tumours. As expected, glycolysis flux is increased in tumours compared with healthy tissues (the Warburg effect2,3), but this increase is insufficient to compensate for low TCA flux in terms of ATP production. Thus, instead of being hypermetabolic, as commonly assumed, solid tumours generally produce ATP at a slower than normal rate. In mouse pancreatic cancer, this is accommodated by the downregulation of protein synthesis, one of this tissue’s major energy costs. We propose that, as solid tumours develop, cancer cells shed energetically expensive tissue-specific functions, enabling uncontrolled growth despite a limited ability to produce ATP.
Original language | English |
---|---|
Pages (from-to) | 349-357 |
Number of pages | 9 |
Journal | Nature |
Volume | 614 |
Issue number | 7947 |
DOIs | |
State | Published - 9 Feb 2023 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2023, The Author(s), under exclusive licence to Springer Nature Limited.
Funding
This work was funded by NIH R01CA163591 to J.D.R.; NIH DP1DK113643 to J.D.R.; Ludwig Cancer Research funding to J.D.R. and Y.K.; Stand Up to Cancer SU2CAACR-DT-20-16 to J.D.R.; American Cancer Society funding to Y.K.; NIH grants 35GM128813 and P30CA072720 to M.W.; NIH CA237347-01A1 and American Cancer Society 134036-RSG-19-165-01-TBG to J.Y.G.; NIH R01CA236936 and Leukemia and Lymphoma Society Scholar Award Scholar Award 1386-23 to D.H.; NIH R50CA211437 to W.L.; R35CA242379 to M.G.V.H.; Allen Foundation and Stand Up to Cancer funding to S.D.; Damon Runyon Foundation/Mark Foundation Postdoctoral Fellowship and K99CA273517 to C.R.B.; New Jersey Commission on Cancer Research grant COCR22PDF002 to V.d.S.-D.; the Charles H. Revson Senior Fellowship in Biomedical Science to Y.H.; NIH F32DK127843 to W.D.L.; New Jersey Commission on Cancer Research postdoctoral fellowship to A.R.; and T32GM007388 to C.S.R.J.
Funders | Funder number |
---|---|
Damon Runyon Foundation/Mark Foundation | K99CA273517 |
New Jersey Commission on Cancer | T32GM007388 |
New Jersey Commission on Cancer Research | COCR22PDF002 |
National Institutes of Health | R01CA163591, DP1DK113643 |
American Cancer Society | CA237347-01A1, 134036-RSG-19-165-01-TBG, 35GM128813, R01CA236936, P30CA072720 |
Charles H. Revson Foundation | F32DK127843 |
Leukemia and Lymphoma Society | 1386-23, R50CA211437, R35CA242379 |
Ludwig Institute for Cancer Research | SU2CAACR-DT-20-16 |